When Steve Sanghera co-founded Inventus in 2020 alongside Chairman Jim Michel, the mission was clear – to tackle the long-standing inefficiencies of clinical trials. Trials were too complex, too expensive and often, delayed by fragmented systems and outdated technology. For Sanghera, the solution lay in creating bespoke, patient-first technology that would transform the way therapies are tested and delivered.
“From day one, our vision has been to create a globally inclusive, end-to-end technology platform for clinical trials,” says Sanghera, now CEO.
“Today, Inventus is pioneering smarter, safer and more efficient clinical trials, always with the patient experience at the heart of what we do.”
A Unique Approach to a Complex Challenge
Clinical trials are notoriously difficult to modernise, but Inventus is uniquely positioned to meet that challenge. The company blends deep expertise in telecoms and life sciences to create purpose-built hardware and software solutions for the sector.
This holistic approach means every device, connection and piece of data is managed seamlessly – reducing delays, cutting costs and ensuring strict regulatory compliance.
Inventus also stands apart as the world’s first and only Clinical Data Plan Operator (CDPO). This distinction allows the company to provide global eSIM connectivity and device management at scale, giving sponsors and CROs full control and efficiency while keeping the patient journey front and centre.
Devices Designed for Global Inclusivity
Central to the Inventus offering are its proprietary devices, the CT1 and CT7. With 500,000 shipped with certification in 70+ countries and supporting 586 languages, they were designed with global inclusivity in mind.
“Patient participation is critical to clinical trial success,” explains Sanghra. “By removing barriers – from language to technological complexity – we make trials more accessible, leading to more representative data and better outcomes for patients worldwide.”
The devices combine intuitive, secure hardware with trial-specific software and global eSIM technology, ensuring seamless connectivity and a consistent experience for patients and sponsors alike.
More from Tech
- Newest Unicorn, Nothing, Plans AI-First Device Launch, Doubling Down On Being Different, Not Better
- Are EU Regulations Protecting Citizens Or Will They Chase Innovation Away?
- Apple Launches New AirPods With Instant Translation: How Do They Work?
- The Rise Of The eSim: What Are The Privacy Concerns?
- From ‘Naughty Step’ To Wi-Fi Blackout: How Parents Discipline In The Digital Age
- The Double-Edged Sword of Digital Identities: More Risks Than Rewards?
- Is Built-In Antivirus Software Enough To Protect You?
- Why We Need More Martins and Kates: The Crucial Role of Advocacy in Raising Awareness of Lasting Power of Attorney
Beyond Hardware: An End-to-End Platform
While devices are key, Inventus’ value lies in its end-to-end ecosystem. The company’s Mobile Device Management solution (the only one built specifically for life sciences) gives pharmaceutical partners real-time oversight and control of devices, networks and data.
Paired with AI-powered analytics, the platform delivers reliable insights that allow pharma companies to focus on innovation rather than troubleshooting.
Proven Impact at Scale
To date, more than 500,000 Inventus devices have been deployed globally, driving meaningful impact for both sponsors and patients. For pharmaceutical companies, the benefits include reduced trial delays, smoother operations and high-quality, actionable data. For patients, the technology ensures a seamless, secure and stress-free trial experience.
Sustainability is another pillar of the Inventus approach. Through its circular economy solution, every device, whether made by Inventus or another manufacturer, can be recycled or repurposed at the end of a trial.
The company’s global logistics network ensures nothing goes to landfill, while partners benefit from certified CO₂ and ESG reporting.
Balancing Innovation and Compliance
In a sector where innovation must go hand-in-hand with regulation, Inventus has built compliance into the DNA of its technology.
Its solutions are developed from the ground up with security and privacy in mind, meeting the strictest global standards while still delivering cutting-edge functionality.
Shaping the Future of Clinical Research
As decentralised and hybrid trials gain traction, Inventus is positioned at the forefront of this transformation. Its connected devices and AI-driven data platforms enable patients to participate from home or local clinics, breaking down geographical barriers and improving recruitment and retention.
“We see Inventus enabling a future where clinical trials are smarter, faster and more patient-centric,” says Sanghera.
“By integrating technology, data and patient insights, we’re paving the way for more inclusive and predictive trials, as well as new preventive digital health solutions.”
What’s Next for Inventus?
Looking ahead, Inventus plans to expand its footprint globally, strengthen collaborations with pharmaceutical leaders and refine its platform with deeper AI-driven insights. Sustainability will remain a core focus, with continued investment in circular economy solutions that help partners meet environmental and reporting goals.
By combining patient-centric design, operational excellence and relentless innovation, Inventus is not just modernising clinical trials – it’s redefining what they can achieve for patients worldwide.
